[1] 毛凯, 王捷. 肝癌合并肝外转移的外科治疗现状[J]. 中华外科杂志, 2019, 57(6): 466-470.
[2] 刘虎, 杨家和, 吴孟超. 原发性肝癌术后肺转移的治疗现状[J]. 中华转移性肿瘤杂志, 2019, 2(4): 1-4.
[3] KUDO M, FINN R S, QIN S, et al.Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial[J]. Lancet, 2018, 391(10126): 1163-1173.
[4] CHENG A L, FINN R S, QIN S, et al.PhaseⅢ trial of lenvatinib (LEN) vs sorafenib (SOR) in first-line treatment of patients (pts) with unresectable hepatocellular carcinoma (uHCC)[J]. J Clin Oncol, 2017, 35(15_suppl): 4001.
[5] 韩玥, 黄振, 姜志超, 等. 肝癌靶向治疗专家共识(草案)[J/CD]. 肝癌电子杂志, 2020, 7(2): 2-11.
[6] ZHAO JD, LIU J, REN Z G, et al.Maintenance of Sorafenib following combined therapy of three-dimensional conformal radiation therapy/intensity-modulated radiation therapy and transcatheter arterial chemoembolization in patients with locally advanced hepatocellular carcinoma: a phase Ⅰ/Ⅱ study[J]. Radiat Oncol, 2010, 5: 12.
[7] 刘琳, 秦叔逵. 分子靶向药物与免疫检查点抑制剂治疗晚期肝细胞癌的研究现状与进展[J]. 临床肿瘤学杂志, 2019, 24(9): 839-849.
[8] 国际肝胆胰协会中国分会, 中华医学会外科学分会肝脏外科学组, 中国临床肿瘤学会(CSCO)肝癌专家委员会. 基于免疫节点抑制剂的肝细胞癌免疫联合治疗多学科中国专家共识(2021版)[J]. 中华肝脏病杂志, 2021, 29(7): 636-647.
[9] DESAI J, DEVA S, LEE J S, et al.Phase ⅠA/ⅠB study of single-agent tislelizumab, an investigational anti-PD-1 antibody, in solid tumors[J]. J Immunother Cancer, 2020, 8(1): e000453.
[10] FUKUMURA D, KLOEPPER J, AMOOZGAR Z, et al.Enhancing cancer immunotherapy using antiangiogenics: opportunities and challenges[J]. Nat Rev Clin Oncol, 2018, 15(5): 325-340.
[11] 彭雪楠, 周爱萍. 肝癌免疫治疗及生物标志物研究进展[J/CD]. 肝癌电子杂志, 2020, 7(4): 17-22.
[12] 徐彬, 朱小东, 黄成, 等. 仑伐替尼联合程序性死亡受体-1抗体治疗不可切除或进展期肝细胞癌的临床疗效[J]. 中华消化外科杂志, 2021, 20(2): 197-204. |
